| Aldesleukin studied in …STUDIED_INderived200 of 402show all (up to 200) |
|---|
| → studied in | NCT06904066Phase 1 · recruiting Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies · 402 trials list this drug (62 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Acute Lymphoblastic Leukemia,Myelodysplastic Syndrome+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03412877Phase 2 · recruiting Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer · 402 trials list this drug (62 active) | — | — | Endocrine Neoplasm,Malignant Breast Neoplasm,Multiple Myeloma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06253520Phase 1 · active not recruiting Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer · 402 trials list this drug (62 active) | — | — | Malignant Breast Neoplasm,Malignant Digestive System Neoplasm,Malignant Genitourinary System Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01174121Phase 2 · recruiting Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer · 402 trials list this drug (62 active) | — | — | Breast Carcinoma,Malignant Pancreatic Neoplasm,Malignant Ovarian Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01857934Phase 2 · completed Therapy for Children With Advanced Stage Neuroblastoma · 402 trials list this drug (62 active) | — | — | Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05267626Phase 1/Phase 2 · recruiting Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer · 402 trials list this drug (62 active) | — | — | Malignant Neoplasm,Solid Neoplasm,Cutaneous Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05155033Phase 2 · recruiting Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma · 402 trials list this drug (62 active) | — | — | Melanoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06236425Phase 1 · completed TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC · 402 trials list this drug (62 active) | — | — | Squamous Cell Carcinoma,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05903937Phase 1 · not yet recruiting Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases · 402 trials list this drug (62 active) | — | — | Cutaneous Melanoma,Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07183852Phase 1 · not yet recruiting Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Cutaneous Melanoma,Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07225439Phase 1 · recruiting Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) · 402 trials list this drug (62 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04562129Phase 2 · active not recruiting IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02133196Phase 2 · recruiting T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer · 402 trials list this drug (62 active) | — | — | Adenocarcinoma,Squamous Cell Carcinoma,Adenosquamous Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06152809Phase 1 · recruiting CIML NK Cells With Venetoclax for AML · 402 trials list this drug (62 active) | — | — | Leukemia,Myeloid Leukemia,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07681596Phase 1/Phase 2 · recruiting A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma · 402 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05483491Phase 1 · recruiting KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer · 402 trials list this drug (62 active) | — | — | Malignant Breast Neoplasm,Malignant Gastric Neoplasm,Malignant Lung Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03190941Phase 1/Phase 2 · recruiting Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients · 402 trials list this drug (62 active) | — | — | Malignant Digestive System Neoplasm,Malignant Gastric Neoplasm,Malignant Pancreatic Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02621021Phase 2 · recruiting A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01038778Phase 1/Phase 2 · active not recruiting Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer · 402 trials list this drug (62 active) | — | — | Clear Cell Renal Cell Carcinoma,Kidney Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02830724Phase 1/Phase 2 · recruiting Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers · 402 trials list this drug (62 active) | — | — | Malignant Breast Neoplasm,Melanoma,Malignant Pancreatic Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00338377Phase 2 · active not recruiting Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06237881Phase 1/Phase 2 · active not recruiting A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors · 402 trials list this drug (62 active) | — | — | Head and Neck Neoplasm,Solid Neoplasm,Lung Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07192900Phase 1 · recruiting Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease · 402 trials list this drug (62 active) | — | — | Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01883297Phase 1 · active not recruiting "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · 402 trials list this drug (62 active) | — | — | Fallopian Tube Neoplasm,Malignant Fallopian Tube Neoplasm,High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02964078Phase 2 · completed Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer · 402 trials list this drug (62 active) | — | — | Malignant Kidney Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05802056Phase 1 · active not recruiting Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis · 402 trials list this drug (62 active) | — | — | Gastric Carcinoma,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06961357Phase 1/Phase 2 · recruiting Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06884670Phase 2 · completed Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study · 402 trials list this drug (62 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07255664Phase 1/Phase 2 · recruiting A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC · 402 trials list this drug (62 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06138587Phase 1 · recruiting Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation · 402 trials list this drug (62 active) | — | — | Leukemia,Myelodysplastic Syndrome,Myeloid Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06321484Phase 1 · recruiting Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer · 402 trials list this drug (62 active) | — | — | Malignant Ovarian Neoplasm,Ovarian Carcinoma,Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07651618Phase 2 · not yet recruiting A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07647068Phase 2 · not yet recruiting Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors · 402 trials list this drug (62 active) | — | — | Gastrointestinal Stromal Tumor,Malignant Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05639972Phase 1/Phase 2 · recruiting E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers · 402 trials list this drug (62 active) | — | — | Human Papillomavirus-Related Adenocarcinoma,Human Papillomavirus-Related Carcinoma,Human Papillomavirus-Related Malignant Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05686226Phase 2 · recruiting E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers · 402 trials list this drug (62 active) | — | — | Malignant Neoplasm,Human Papillomavirus-Related Adenocarcinoma,Human Papillomavirus-Related Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03449108Phase 2 · active not recruiting LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas · 402 trials list this drug (62 active) | — | — | Malignant Solid Neoplasm,Bone Sarcoma,Osteosarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06598371Phase 1/Phase 2 · recruiting A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors · 402 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03745326Phase 1/Phase 2 · terminated Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients · 402 trials list this drug (62 active) | — | — | Malignant Digestive System Neoplasm,Malignant Gastric Neoplasm,Malignant Pancreatic Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05989828Phase 1 · recruiting A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer · 402 trials list this drug (62 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06151847Phase 2 · completed Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01955460Phase 1 · active not recruiting Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03017131Phase 1 · active not recruiting Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · 402 trials list this drug (62 active) | — | — | Primary Peritoneal Carcinoma,Ovarian Carcinoma,Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04673617Phase 1/Phase 2 · completed AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma · 402 trials list this drug (62 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05628883Phase 1 · completed Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma,Conjunctival Melanoma,Cutaneous Melanoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02858310Phase 1/Phase 2 · completed E7 TCR T Cells for Human Papillomavirus-Associated Cancers · 402 trials list this drug (62 active) | — | — | Carcinoma In Situ,Cervical Intraepithelial Neoplasia,Vulvar Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00026312Phase 3 · completed Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma · 402 trials list this drug (62 active) | — | — | Neuroblastoma,Regional Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04426669Phase 1/Phase 2 · completed A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering · 402 trials list this drug (62 active) | — | — | Digestive System Neoplasm,Malignant Digestive System Neoplasm,Malignant Esophageal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05566223Phase 1/Phase 2 · withdrawn CISH Inactivated TILs in the Treatment of NSCLC · 402 trials list this drug (62 active) | — | — | Lung Large Cell Carcinoma,Lung Non-Small Cell Carcinoma,Lung Squamous Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04052334Phase 1 · completed Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma · 402 trials list this drug (62 active) | — | — | Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07389239Phase 1/Phase 2 · not yet recruiting A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. · 402 trials list this drug (62 active) | — | — | Malignant Solid Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07288073Phase 2 · recruiting TIL Therapy in cSCC and MCC · 402 trials list this drug (62 active) | — | — | Malignant Skin Neoplasm,Skin Squamous Cell Carcinoma,Merkel Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05493566early Phase 1 · recruiting Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer · 402 trials list this drug (62 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00923806Phase 1 · terminated Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer · 402 trials list this drug (62 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06626256Phase 1 · withdrawn STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma · 402 trials list this drug (62 active) | — | — | Malignant Solid Neoplasm,Melanoma,Malignant Pancreatic Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01319565Phase 2 · completed Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... · 402 trials list this drug (62 active) | — | — | Malignant Skin Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03260504Phase 1 · terminated Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer · 402 trials list this drug (62 active) | — | — | Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00534469Phase 2 · completed Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R · 402 trials list this drug (62 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01697527Phase 2 · active not recruiting Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies · 402 trials list this drug (62 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05194735Phase 1/Phase 2 · terminated Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors · 402 trials list this drug (62 active) | — | — | Malignant Pancreatic Neoplasm,Lung Non-Small Cell Carcinoma,Lung Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05296564Phase 1/Phase 2 · recruiting Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers · 402 trials list this drug (62 active) | — | — | Malignant Neoplasm,Melanoma,Soft Tissue Sarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04812470Phase 1 · completed Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases · 402 trials list this drug (62 active) | — | — | Cutaneous Melanoma,Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05385705Phase 1 · terminated A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020 · 402 trials list this drug (62 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06690281Phase 2 · withdrawn A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies · 402 trials list this drug (62 active) | — | — | Malignant Neoplasm,Malignant Pancreatic Neoplasm,Hepatocellular Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06204991Phase 1 · recruiting To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05883449Phase 2 · terminated Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL · 402 trials list this drug (62 active) | — | — | Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02652455early Phase 1 · completed Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Malignant Skin Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02775292Phase 1 · completed Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 · 402 trials list this drug (62 active) | — | — | Neoplasm,Adult Solid Neoplasm,Childhood Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07063875Phase 1/Phase 2 · recruiting Adding IL-2 to Tebentafusp to Eradicate Cancer Progression · 402 trials list this drug (62 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06119685Phase 1/Phase 2 · recruiting IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers · 402 trials list this drug (62 active) | — | — | Liquid Tumor,Multiple Myeloma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00994643Phase 2 · completed Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma · 402 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03610490Phase 2 · terminated Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma · 402 trials list this drug (62 active) | — | — | Malignant Solid Neoplasm,Ovarian Carcinoma,Colorectal Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02278887Phase 3 · completed Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04643574Phase 1 · active not recruiting NeoTIL in Advanced Solid Tumors · 402 trials list this drug (62 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03475134Phase 1 · completed TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL) · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04887259Phase 1 · terminated Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML · 402 trials list this drug (62 active) | — | — | Multiple Myeloma,Acute Myeloid Leukemia,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02500576Phase 2 · completed Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02926053Phase 1 · completed TIL Therapy for Metastatic Renal Cell Carcinoma · 402 trials list this drug (62 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06532799Phase 1/Phase 2 · recruiting TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer · 402 trials list this drug (62 active) | — | — | Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06532812Phase 1/Phase 2 · recruiting TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer · 402 trials list this drug (62 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03318900Phase 1/Phase 2 · completed T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer · 402 trials list this drug (62 active) | — | — | Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05141474early Phase 1 · recruiting Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors · 402 trials list this drug (62 active) | — | — | Carcinoma,Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06530303Phase 1/Phase 2 · recruiting Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer · 402 trials list this drug (62 active) | — | — | Malignant Colorectal Neoplasm,Malignant Colon Neoplasm,Rectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06640582Phase 1/Phase 2 · recruiting TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas · 402 trials list this drug (62 active) | — | — | Glioblastoma,Glioma,Meningioma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03296137Phase 1/Phase 2 · completed Adoptive Cell Therapy Across Cancer Diagnoses · 402 trials list this drug (62 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06538012Phase 1/Phase 2 · recruiting TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer · 402 trials list this drug (62 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01740557Phase 1/Phase 2 · completed Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02027935Phase 2 · completed CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03476174Phase 2 · terminated Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03546426Phase 1 · active not recruiting Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies · 402 trials list this drug (62 active) | — | — | Malignant Neoplasm,Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03691376Phase 1 · terminated Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · 402 trials list this drug (62 active) | — | — | Primary Peritoneal Carcinoma,Ovarian Carcinoma,Platinum-Resistant Primary Peritoneal Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03891706Phase 1 · recruiting Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors · 402 trials list this drug (62 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04166006Phase 2 · recruiting A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers. · 402 trials list this drug (62 active) | — | — | Neuroendocrine Tumor,Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03658785Phase 1/Phase 2 · unknown Immunotherapy for the Treatment of Advanced Solid Tumor · 402 trials list this drug (62 active) | — | — | Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03233828Phase 3 · terminated Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2 · 402 trials list this drug (62 active) | — | — | Melanoma,Melanoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06504875not yet recruiting Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer · 402 trials list this drug (62 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06504901not yet recruiting Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases · 402 trials list this drug (62 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03098355Phase 1/Phase 2 · withdrawn Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies · 402 trials list this drug (62 active) | — | — | B-Cell Malignant Neoplasm,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04102436Phase 2 · withdrawn Non-Viral TCR Gene Therapy · 402 trials list this drug (62 active) | — | — | Malignant Breast Neoplasm,Lung Non-Small Cell Carcinoma,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00019448Phase 2 · completed Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00020267Phase 1 · completed Vaccine Therapy in Treating Patients With Metastatic Cancer · 402 trials list this drug (62 active) | — | — | Malignant Breast Neoplasm,Malignant Eye Neoplasm,Melanoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00020475Phase 2 · completed Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye · 402 trials list this drug (62 active) | — | — | Uveal Melanoma,Ocular Melanoma with Extraocular Extension | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03068624Phase 1 · unknown Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma · 402 trials list this drug (62 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03912831Phase 1 · terminated Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers · 402 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06121557Phase 1 · recruiting Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer · 402 trials list this drug (62 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06121570Phase 1 · recruiting Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer · 402 trials list this drug (62 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01823198Phase 1/Phase 2 · completed Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies · 402 trials list this drug (62 active) | — | — | Myelodysplastic Syndrome,Acute Erythroid Leukemia,Acute Megakaryoblastic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03240861Phase 1 · terminated Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer · 402 trials list this drug (62 active) | — | — | Malignant Neoplasm,Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03450122Phase 1 · completed Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma · 402 trials list this drug (62 active) | — | — | Myxoid Liposarcoma,Synovial Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00617799completed Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma,Malignant Kidney Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03501381Phase 2 · active not recruiting High Dose IL 2 and Entinostat in RCC · 402 trials list this drug (62 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05981001Phase 1/Phase 2 · recruiting Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer · 402 trials list this drug (62 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05981014Phase 1/Phase 2 · recruiting Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer · 402 trials list this drug (62 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02774291early Phase 1 · terminated Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes · 402 trials list this drug (62 active) | — | — | Malignant Neoplasm,Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02748564Phase 2 · terminated Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma,Cutaneous Melanoma,Head and Neck Mucosal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02203604Phase 2 · terminated High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00003027Phase 3 · completed Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05895370Phase 1 · unknown HPV-T in HPV-16 Positive Recurrent or Metastatic Solid Tumors · 402 trials list this drug (62 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02620865Phase 1/Phase 2 · completed BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer · 402 trials list this drug (62 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Carcinoma,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01995344Phase 2 · terminated TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04354025Phase 2 · withdrawn Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML · 402 trials list this drug (62 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05798546Phase 1 · unknown Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) · 402 trials list this drug (62 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03287674Phase 1/Phase 2 · completed TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer · 402 trials list this drug (62 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03928275Phase 2/Phase 3 · withdrawn The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01993719Phase 2 · completed Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02414945Phase 1/Phase 2 · completed TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients · 402 trials list this drug (62 active) | — | — | Pleural Mesothelial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00945269Phase 1/Phase 2 · terminated Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01807182Phase 2 · completed Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01946373Phase 1 · unknown T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01700946Phase 2 · completed Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma · 402 trials list this drug (62 active) | — | — | Childhood B Acute Lymphoblastic Leukemia,Childhood B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01640301Phase 1/Phase 2 · terminated Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant · 402 trials list this drug (62 active) | — | — | Secondary Acute Myeloid Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia Post Cytotoxic Therapy+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05122221Phase 1 · unknown CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers · 402 trials list this drug (62 active) | — | — | Malignant Head and Neck Neoplasm,Malignant Anal Neoplasm,Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02111850Phase 1/Phase 2 · completed T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive · 402 trials list this drug (62 active) | — | — | Malignant Breast Neoplasm,Melanoma,Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04893915Phase 2 · withdrawn Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS · 402 trials list this drug (62 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00924326Phase 1/Phase 2 · completed CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma · 402 trials list this drug (62 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02770820Phase 1/Phase 2 · terminated Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia · 402 trials list this drug (62 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02408016Phase 1/Phase 2 · terminated Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma · 402 trials list this drug (62 active) | — | — | Pleural Malignant Mesothelioma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02989714Phase 1/Phase 2 · completed Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer · 402 trials list this drug (62 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00414765Phase 4 · completed Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01967823Phase 2 · completed T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer · 402 trials list this drug (62 active) | — | — | Malignant Breast Neoplasm,Melanoma,Meningioma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03992326Phase 1 · terminated Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors · 402 trials list this drug (62 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03213964Phase 1 · completed Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int · 402 trials list this drug (62 active) | — | — | Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04383067Phase 2 · unknown A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients · 402 trials list this drug (62 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04536922Phase 2 · withdrawn Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab · 402 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02757391Phase 1 · terminated CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors · 402 trials list this drug (62 active) | — | — | Digestive System Carcinoma,Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01704716Phase 3 · recruiting High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) · 402 trials list this drug (62 active) | — | — | Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00083941Phase 2 · completed A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer · 402 trials list this drug (62 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00505635Phase 2 · terminated Biochemotherapy With Temozolomide for Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00698009Phase 2 · terminated Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma · 402 trials list this drug (62 active) | — | — | Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04135092no longer available Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab · 402 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03778619Phase 1/Phase 2 · unknown MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin · 402 trials list this drug (62 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03506802Phase 1 · withdrawn TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma · 402 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01701479Phase 1/Phase 2 · unknown Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2) · 402 trials list this drug (62 active) | — | — | Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01370213Phase 2 · completed NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases · 402 trials list this drug (62 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02354690Phase 1/Phase 2 · completed Vemurafenib and TIL Therapy for Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02316964Phase 1 · completed Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia · 402 trials list this drug (62 active) | — | — | Secondary Acute Myeloid Leukemia,Adult Acute Myeloid Leukemia,Acute Myeloid Leukemia with del(5q)+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02379195Phase 1/Phase 2 · completed Peginterferon and TIL Therapy for Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03935347Phase 2 · withdrawn Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy · 402 trials list this drug (62 active) | — | — | Bladder Urothelial Carcinoma,Urethral Urothelial Carcinoma,Renal Pelvis Urothelial Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02390739Phase 1/Phase 2 · withdrawn Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer · 402 trials list this drug (62 active) | — | — | Malignant Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00304460Phase 1 · completed Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer · 402 trials list this drug (62 active) | — | — | Melanoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01218867Phase 1/Phase 2 · terminated CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer · 402 trials list this drug (62 active) | — | — | Malignant Neoplasm,Melanoma,Kidney Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01369875Phase 2 · terminated Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Malignant Skin Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01585415Phase 1 · terminated Vemurafenib and White Blood Cell Therapy for Advanced Melanoma · 402 trials list this drug (62 active) | — | — | Malignant Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00670748Phase 2 · terminated Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer · 402 trials list this drug (62 active) | — | — | Malignant Neoplasm,Melanoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01583686Phase 1/Phase 2 · terminated CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer · 402 trials list this drug (62 active) | — | — | Malignant Mesothelioma,Malignant Lung Neoplasm,Malignant Pancreatic Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01289678Phase 2 · terminated Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia · 402 trials list this drug (62 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01454596Phase 1/Phase 2 · completed CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII · 402 trials list this drug (62 active) | — | — | Glioblastoma,Malignant Glioma,Gliosarcoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03111901Phase 1/Phase 2 · withdrawn Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer · 402 trials list this drug (62 active) | — | — | Melanoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02153905Phase 1/Phase 2 · terminated T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive · 402 trials list this drug (62 active) | — | — | Malignant Breast Neoplasm,Melanoma,Malignant Bladder Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00784524Phase 2 · terminated Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca · 402 trials list this drug (62 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00853021Phase 2 · completed Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney · 402 trials list this drug (62 active) | — | — | Malignant Kidney Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01258855Phase 2 · completed Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery · 402 trials list this drug (62 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00002787Phase 1 · completed Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation · 402 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00923390Phase 1 · terminated Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor · 402 trials list this drug (62 active) | — | — | Kidney Neoplasm,Malignant Kidney Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02070406Phase 1 · terminated Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies · 402 trials list this drug (62 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00002746Phase 1 · completed Interleukin-2 in Treating Patients With Myelodysplastic Syndrome · 402 trials list this drug (62 active) | — | — | Leukemia,Myelodysplastic Syndrome,Myelodysplastic/Myeloproliferative Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01124734Phase 2 · completed High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01630564Phase 1 · terminated Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies · 402 trials list this drug (62 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01814046Phase 2 · terminated Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma · 402 trials list this drug (62 active) | — | — | Ocular Melanoma,Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01795976Phase 2 · terminated NY-ESO-1 T Cells in OG Cancer · 402 trials list this drug (62 active) | — | — | Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00085436Phase 2 · completed DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC · 402 trials list this drug (62 active) | — | — | Malignant Kidney Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01702896Phase 2 · terminated Interleukin-2 in Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01585428Phase 2 · completed Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers · 402 trials list this drug (62 active) | — | — | Malignant Oropharyngeal Neoplasm,Malignant Penile Neoplasm,Malignant Vaginal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01702909Phase 2 · terminated Interleukin-2 in Metastatic Kidney Cancer · 402 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01181258Phase 2 · completed Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies · 402 trials list this drug (62 active) | — | — | Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00274846Phase 2 · completed Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia · 402 trials list this drug (62 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00303667Phase 1/Phase 2 · completed Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant · 402 trials list this drug (62 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00354172Phase 2 · terminated Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers. · 402 trials list this drug (62 active) | — | — | Leukemia,Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00376805Phase 2 · terminated Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer · 402 trials list this drug (62 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00625729Phase 1/Phase 2 · terminated Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia · 402 trials list this drug (62 active) | — | — | Leukemia,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00652899Phase 2 · terminated Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer · 402 trials list this drug (62 active) | — | — | Malignant Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00726739Phase 2 · completed Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00871689Phase 2 · terminated Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML · 402 trials list this drug (62 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01105650Phase 2 · completed Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer · 402 trials list this drug (62 active) | — | — | Malignant Breast Neoplasm,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01464359Phase 2 · terminated T-Cell Depleted Double UCB for Refractory AML · 402 trials list this drug (62 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01639456Phase 2 · withdrawn CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission · 402 trials list this drug (62 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00005993Phase 1 · terminated Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer · 402 trials list this drug (62 active) | — | — | Lymphoma,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00019682Phase 3 · completed Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00001827Phase 2 · terminated p53 Vaccine for Ovarian Cancer · 402 trials list this drug (62 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02111863Phase 2 · terminated Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma · 402 trials list this drug (62 active) | — | — | Malignant Skin Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02280811Phase 1/Phase 2 · completed T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers · 402 trials list this drug (62 active) | — | — | Malignant Oropharyngeal Neoplasm,Malignant Penile Neoplasm,Malignant Vaginal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |